Tip:
Highlight text to annotate it
X
{\rtf1\ansi\ansicpg1252\cocoartf1138\cocoasubrtf510 {\fonttbl\f0\fswiss\fcharset0 ArialMT;}
{\colortbl;\red255\green255\blue255;} \margl1440\margr1440\vieww10800\viewh8400\viewkind0
\deftab720 \pard\tx560\tx1120\tx1680\tx2240\tx2800\tx3360\tx3920\tx4480\tx5040\tx5600\tx6160\tx6720\pardeftab720\pardirnatural\qj
\f0\fs24 \cf0 \expnd0\expndtw0\kerning0 Dr. Mark F. Kozloff: When I make a decision
about chemotherapy in patients with colorectal cancer I take into effect their stage, stage
1, 2, 3, and 4 and certainly that will help me to determine if a patient needs chemotherapy.
In some circumstances for stage 2 patients, it is not always clear on how much help that
chemotherapy will be and if you take all patients you only get about of 2.5% benefit. In some
patients, I order Oncotype DX because it can help me tell the prognosis in that patient
a little bit more exacting than just looking at all stage 2 patients together and that
can also help me tell if the patient or help me recommend or not recommend should they
be on adjuvant therapy. I think most important giving that information to patients can help
them know more exacting what their prognosis is and it may also help that patient determine
if they should or should not be on chemotherapy. So I offer the test to the patients many times
with stage 2 patients and I tell them the benefits as well as non-benefits of doing
the test, but I do feel that in many patients it can be helpful at clarifying prognosis
and can be helpful to some patients in deciding on chemotherapy. So in summary, I do order
the test on some patients, but not all patients and I do feel that it can be helpful to those
patients.}